Metagenomi, Inc. Holds Annual Stockholders Meeting

Metagenomi, Inc. ( (MGX) ) just unveiled an announcement.

On June 10, 2025, Metagenomi, Inc. held its annual meeting of stockholders virtually, where a quorum was established with 18,765,221 shares present or represented by proxy. During the meeting, stockholders elected Willard H. Dere, M.D. as a Class I Director until 2028 and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Spark’s Take on MGX Stock

According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.

Metagenomi, Inc.’s overall stock score reflects strong revenue growth and promising corporate developments in genome editing. However, the score is tempered by ongoing profitability challenges and negative cash flows. Technical indicators suggest stable but cautious market sentiment. Valuation concerns due to negative earnings impact the overall attractiveness for risk-averse investors.

To see Spark’s full report on MGX stock, click here.

More about Metagenomi, Inc.

Average Trading Volume: 374,220

Technical Sentiment Signal: Sell

Current Market Cap: $58.69M

Learn more about MGX stock on TipRanks’ Stock Analysis page.